Comparative Pharmacology
Head-to-head clinical analysis: ADZENYS ER versus EVEKEO ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADZENYS ER versus EVEKEO ODT.
ADZENYS ER vs EVEKEO ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADZENYS ER is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
EVEKEO ODT (amphetamine) is a CNS stimulant that increases extracellular levels of dopamine and norepinephrine by blocking their reuptake into presynaptic neurons and inhibiting monoamine oxidase, leading to enhanced neurotransmission.
Adults: Initial 5-10 mg orally once daily; titrate in 5-10 mg increments weekly to optimal response; max 60 mg/day.
0.25 mg orally as a single dose; may repeat once after 30 minutes if required.
None Documented
None Documented
6-8 hours in adults; in children 3-6 hours, requiring twice-daily dosing for sustained effect
3-5 hours in healthy adults; prolonged in renal impairment (up to 20 hours in ESRD)
70% renal (30% unchanged, 40% as metabolites), 30% fecal/biliary
Renal: approximately 50% as unchanged drug and metabolites; fecal: minimal (<10%)
Category C
Category C
CNS Stimulant
CNS Stimulant